Salemonline Journal

Celiac Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Celiac Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 21
22:44 2021
Celiac Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
DelveInsight’s “Celiac Disease Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Celiac Disease pipeline landscapes. It comprises Celiac Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Celiac Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Celiac Disease pipeline products.

DelveInsight’s Celiac Disease Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the Celiac Disease pipeline landscapes. It comprises Celiac Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Celiac Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Celiac Disease pipeline products.   

  

Some of the key takeaways of the Celiac Disease Pipeline Report

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as ImmunoGenX, 9Meters Biopharma, Cour Pharmaceutical/ Takeda, Provention Bio, Falk Pharma and Zedira, Precigen ActoBio, Takeda, etc., are developing therapies for the treatment of Celiac Disease.

  • Emerging therapies such as Latiglutenase (IMGX003), Larazotide Acetate, CNP-101/ TAK-101, PRV-015 (AMG 714), ZED1227, AG017, TAK-062, are expected to have a significant impact on the  Celiac Disease market in the coming years.

  • The market size of Celiac Disease in the seven major markets was discovered to be USD 1,242.8 Million in 2017.

Get an overview of pipeline landscape @ Celiac Disease Clinical Trials Analysis  

Celiac disease is an autoimmune disease that’s triggered once you eat gluten. It’s also called celiac sprue, nontropical sprue, or gluten-sensitive enteropathy. Gluten is a protein in wheat, rye, and other grains. It’s what makes dough elastic and provides bread with its chewy texture.

Celiac Disease Emerging Drugs

  • Latiglutenase (IMGX003) by ImmunoGenX

  • Larazotide Acetate by 9 Meters Biopharma

  • CNP-101/ TAK-101 by Cour Pharmaceutical/ Takeda

  • PRV-015 (AMG 714) by Provention Bio

  • ZED1227 by Falk Pharma and Zedira

  • AG017 by Precigen ActoBio

  • TAK-062 by Takeda

  • And others.

Scope of Celiac Disease Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: ImmunoGenX, 9Meters Biopharma, Cour Pharmaceutical/ Takeda, Provention Bio, Falk Pharma and Zedira, Precigen ActoBio, Takeda, and others.

  • Pipeline Therapies: Latiglutenase (IMGX003), Larazotide Acetate, CNP-101/ TAK-101, PRV-015 (AMG 714), ZED1227, AG017, TAK-062, and others.

Table of Contents

1

Celiac Disease Report Introduction

2

Celiac Disease Executive Summary

3

Celiac Disease Overview

4

Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5

Celiac Disease Pipeline Therapeutics

6

Celiac Disease Late Stage Products (Phase II/III)

7

Celiac Disease Mid Stage Products (Phase II)

8

Celiac Disease Early Stage Products (Phase I)

9

Celiac Disease Preclinical Stage Products

10

Celiac Disease Therapeutics Assessment

11

Celiac Disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Celiac Disease Key Companies

14

Celiac Disease Key Products

15

Celiac Disease Unmet Needs

16 

Celiac Disease Market Drivers and Barriers

17

Celiac Disease Future Perspectives and Conclusion

18

Celiac Disease Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Celiac Disease Drugs Pipeline Report  

Related Reports:

Celiac Disease Market 

DelveInsight’s Celiac Disease – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Celiac Disease Epidemiology 

DelveInsight’s ‘ Celiac Disease- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted  Celiac Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles